The South & Central America human leukocyte antigen (HLA) testing market is expected to grow from US$ 45.71 million in 2022 to US$ 67.38 million by 2028; it is estimated to grow at a CAGR of 6.7% from 2022 to 2028.
Human leukocyte antigens (HLAs) are specialized proteins present on all cell surfaces of the human body except red blood cells. HLA testing has significant application in organ transplantation, which can be recommended as a part of the treatment of kidney failure, chronic liver cirrhosis, and chronic heart disease, among other medical issues. The growing prevalence of chronic diseases and organ failure leads to high demand for organ transplant procedures, as well as HLA testing. Before transplantation, HLA testing is performed to check tissue compatibility between patients and donors to avoid graft rejection. In recent years, transplantation has become a successful practice area. Governments of various countries are taking initiatives to spread awareness about the need for organ donation and the benefits of organ transplantation in certain treatment procedures. Thus, the growing demand for organ transplantation leads to the requirement of a more substantial number of HLA testing kits and consumables, driving the HLA testing market.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the South & Central America human leukocyte antigen (HLA) testing market at a notable CAGR during the forecast period.
The South & Central America human leukocyte antigen (HLA) testing market is segmented into product & services, technology, end user, and country. Based on product & services, the market is segmented into reagents & consumables, instruments, and software & services. In terms of technology, the South & Central America human leukocyte antigen (HLA) testing market is divided into molecular assay technologies and non-molecular assay technologies. The molecular assay technologies segment is sub segmented into PCR-based molecular assays, sequencing-based molecular assays, and others. Based on end user, the market is divided into independent reference laboratories, hospital and transplant centers, and others. Based on country, the South & Central America human leukocyte antigen (HLA) testing market is segmented into Brazil, Argentina, and the Rest of South & Central America.
THERMO FISHER SCIENTIFIC INC.; CareDx; QIAGEN; Illumina; Bio-Rad Laboratories, Inc.; F. HOFFMANN-LA ROCHE LTD.; and Takara Bio Inc. are among the major companies operating in the South & Central America human leukocyte antigen (HLA) testing market.